J&J fi­nal­izes $25M set­tle­ment, lay­ing Rem­i­cade an­titrust al­le­ga­tions to rest

A Penn­syl­va­nia fed­er­al judge on Wednes­day ce­ment­ed a $25 mil­lion set­tle­ment in a class ac­tion suit al­leg­ing John­son & John­son blocked biosim­i­lar com­pe­ti­tion to its im­muno­sup­pres­sive drug Rem­i­cade.

First ap­proved in 1998 for Crohn’s dis­ease, Rem­i­cade (a TNF in­hibitor bi­o­log­ic al­so known as in­flix­imab) has since been cleared in a slate of oth­er im­mune-me­di­at­ed con­di­tions, in­clud­ing ul­cer­a­tive col­i­tis, pso­ri­at­ic arthri­tis and rheuma­toid arthri­tis. How­ev­er, the year­ly cost for some pa­tients reach­es $26,000, ac­cord­ing to a com­plaint up­dat­ed in 2018.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER